Toll-like receptors in Alzheimer’s disease: A therapeutic perspective

CNS and Neurological Disorders - Drug Targets

Volumn 13, Issue 9, 2014, Pages 1542-1558

  Gambuzza, Maria E ^a   Sofo, Vincenza ^b   Salmeri, Francesca M ^b   Soraci, Luca ^b   Marino, Silvia ^c   Bramanti, Placido ^c  

^a Ministry of Health Territorial Office of Messina   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

Author keywords

Alzheimer s disease; Amyloid beta; Autophagy; Inflammation; Phagocytosis; Toll like receptors; Toll like receptortargeted therapeutics

Indexed keywords

AGATOLIMOD; AMYLOID BETA PROTEIN; ANA 773; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; CD14 ANTIGEN; CQ 07001; GARDIQUIMOD; IBUDILAST; IMIQUIMOD; IPH 3102; KRESTIN; MACROPHAGE ACTIVATING LIPOPEPTIDE 2; MCT 465; MYELOID DIFFERENTIATION FACTOR 88; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; OM 174; PHOSPHORYL LIPID A; POLYADENYLIC POLYURIDYLIC ACID; POLYINOSINIC POLYCYTIDYLIC ACID; RINTATOLIMOD; TECEMOTIDE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; AUTOPHAGY; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DRUG TARGETING; HUMAN; INNATE IMMUNITY; MICROGLIA; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PHAGOCYTOSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); SIGNAL TRANSDUCTION;

EID: 84920563152     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527313666140806124850     Document Type: Article

References (272)

1. Salminen A, Ojala J, Kauppinen A, Kaamiranta K, Suuronen T. Inflammation in Alzheimer’s disease: amyloid-beta oligomers trigger innate immunity defence via pattern recognition receptors. Progr Neurobiol 2009; 87(3): 181-94.
2. Blasius AL, Beutler B. Intracellular toll-like receptors. Immunity 2010; 32(3): 305-15.
3. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010; 11(5): 373-84.
4. Lehnardt S. Innate immunity and neuroinflammation in the CNS: the role of microglia in Toll-like receptor-mediated neuronal injury. Glia 2010; 58(3): 253-63.
5. Bajramovic JJ. Regulation of innate immune responses in the central nervous system. CNS Neurol Disord Drug Targets 2011; 10(1): 4-24.
6. Holley MM, Zhang Y, Lehrmann E, et al. TLR2-9 crosstalk dictates IL-12 family cytokine production in microglia. Glia 2012; 60(1): 29-42.
7. Ousman SS, Kubes P. Immune surveillance in the central nervous system. Nat Neurosci 2012; 15(8): 1096-101.
8. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23(11): 549-55.
9. Koenigsknecht-Talboo J, Landreth GE. Microglial phagocytosis induced by fibrillar Aβ and IgGs are differentially regulated by proinflammatory cytokines. J Neurosci 2005; 25(36): 8240-9.
10. Zelcer N, Khanlou N, Clare R, et al. Attenuation of neuroinflammation and Alzheimer's disease pathology by liver receptors. Proc Natl Acad Sci USA 2007; 104(25): 10601-6.
11. Farina C, Aloisi F, Meinl E. Astrocytes are active players in cerebral innate immunity. Trends Immunol 2007; 28(3): 138-45.
12. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer’s disease. Neurobiol Aging 2000; 21(3): 383-421.
13. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid β- peptide. Nat Rev Mol Cell Biol 2007; 8(2): 101-12
14. Rivest S. Regulation of innate immune responses in the brain. Nat Rev Immunol 2009; 9(6): 383-421.
15. Gorelick PB. Role of inflammation in cognitive impairment: results of observational epidemiological studies and clinical trials. Ann NY Acad Sci 2010; 1207: 155-62.
16. Cashman JR, Ghirmai S, Abel KJ, Fiala M. Immune defects in Alzheimer’s disease: new medications development. BMC Neurosci 2008; 9(2): S13.
17. Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol 2011; 7(3): 137-52.
18. Luhrs T, Ritter C, Adrian M, et al. 3D structure of Alzheimer's amyloidbeta (1-42) fibrils. Proc Natl Acad Sci USA 2005; 102(48): 17342-7.
19. Yu WH, Cuervo AM, Kumar A, et al. Macroautophagy- a novel β- amyloid peptide-generating pathway activated in Alzheimer's disease. J Cell Biol 2005; 171(1): 87-98.
20. Nixon RA. Autophagy, amyloidogenesis and Alzheimer disease. J Cell Sci 2007; 120: 4081-91.
21. Abbas N, Bednar I, Mix E, et al. Up-regulation of the inflammatory cytokines IFN-γ and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APPSWE transgenic mice. J Neuroimmunol 2002; 126(1-2): 50-7.
22. Reed-Geaghan EG, Savage JC, Hise AG, Landreth GE. CD14 and TLR2 and 4 are required for Fibrillar AβStimulated Microglial Activation. J Neurosci 2009; 29(38): 11982-92.
23. Eriksson M, Meadows SK, Basu S, et al. TLRs mediate IFNgamma production by human uterine NK cells in endometrium. J Immunol 2006; 176(10): 6219-24.
24. Kaisho T, Akira S. Toll-like receptors function and signaling. J Allergy Clin Immunol 2006; 117(5): 979-87.
25. Yoshimoto T, Nakanishi K. Roles of IL-18 in basophils and mast cells. Allergol Int 2006; 55(2): 105-13.
26. Gerondakis S, Grumont RJ, Banerjee A. Regulating B-cell activation and survival in response to TLR signals. Immunol Cell Biol 2007; 85(6): 471-5.
27. Sabroe I, Whyte MK. Toll-like receptors (TLR)-based networks regulate neutrophilic inflammation in respiratory disease. Biochem Soc Trans 2007; 35(Pt 6): 1492-5.
28. Sutmuller R, Garritsen A, Adema GJ. Regulatory T cells and tolllike receptors: regulating the regulators. Ann Rheum Dis 2007; 66(S3): 91-5.
29. Iwamura C, Nakayama T. Toll-like receptors in the respiratory system: their roles in inflammation. Curr Allergy Asthma Rep 2008; 8(1): 7-13.
30. Gibson FC 3rd, Ukai T, Genco CA. Engagement of specific innate immune signaling pathways during Porphyromonas gingivalis induced chronic inflammation and atherosclerosis. Front Biosci 2008; 13: 2041-59.
31. Carty M, Bowie AG. Evaluating the role of Toll-like receptors in diseases of the central nervous system. Biochem Pharmacol 2011; 81(7): 825-37.
32. Olson JK, Miller SD. Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J Immunol 2004; 173(6): 3916-24.
33. Bowman CC, Rasley A, Tranguch SL, Marriott I. Cultured astrocytes express toll-like receptors for bacterial products. Glia 2003; 43(3): 281-91.
34. Aravalli RN, Peterson PK, Lokensgard JR. Toll-like receptors in defense and damage of the central nervous system. J Neuroimmune Pharmacol 2007; 2(4): 297-312.
35. Tang SC, Arumugam TV, Xu X, et al. Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits. Proc Natl Acad Sci USA 2007; 104(34): 13798-803.
36. Rock FL, Hardiman G, Timans JC, Kastelein RA, Bazan JF. A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci USA 1998; 95(2): 588-93.
37. Chen K, Huang J, Gong W, et al. Toll-like receptors in inflammation, infection and cancer. Int Immunopharmacol 2007; 7(10): 1271-85.
38. Romagne F. Current and future drugs targeting one class of innate immunity receptors: the Toll-like receptors. Drug Discov Toda 2007; 12(1-2): 80-7.
39. Wang RF, Miyahara Y, Wang HY. Toll-like receptors and immune regulation: implications for cancer therapy. Oncogene 2008; 27(2): 181-9.
40. Rasmussen SB, Reinert LS, Paludan SR. Innate recognition of intracellular pathogens: detection and activation of the first line of defense. APMIS 2009; 117(5-6): 323-7.
41. Underhill DM. Collaboration between the innate immune receptors dectin-1: TLRs, and Nods. Immunol Rev 2007; 219: 75-87.
42. Vogel SN, Fitzgerald KA, Fenton MJ. TLRs: differential adapter utilization by Toll-like receptors mediates TLR-specific patterns of gene expression. Mol Interv 2003; 3(8): 466-77.
43. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124(4): 783-801.
44. Jin MS, Lee JO. Structures of the Toll-like receptor family and its ligand complexes. Immunity 2008; 29(2): 182-91.
45. Kenny EF, O’Neill LA. Signaling adaptors used by Toll-like receptors: an update. Cytokine 2008; 43(3): 342-9.
46. Carpenter S, O’Neill LA. Recent insights into the structure of Tolllike receptors and post-translational modifications of their associated signaling proteins. Biochem J 2009; 422(1): 1-10.
47. Monie TP, Moncrieffe MC, Gay NJ. Structure and regulation of cytoplasmic adapter proteins involved in innate immune signaling. Immunol Rev 2009; 227(1): 161-75.
48. Botos I, Segal DM, Davies DR. The structural biology of Toll-like receptors. Structure 2011; 19(4): 447-59.
49. Lin Q, Fang D, Fang J, Su SB. The essential roles of Toll-like receptor signaling pathways in sterile inflammatory diseases. Int Immunopharmacol 2011; 11(10): 1422-32.
50. Means TK, Golenbock DT, Fenton MJ. Structure and function of Toll-like receptor proteins. Life Sci 2000; 68(3): 241-58.
51. Barton GM, Medzhitov R. Toll-like receptors and their ligands. Curr Top Microbiol Immunol 2002; 270: 81-92.
52. Takeda K, Akira S. TLR signaling pathways. Semin Immunol 2004; 16(1): 3-9.
53. Kawai T, Akira S. Signaling to NF-kappa B by Toll-like receptors. Trends Mol Med 2007; 13(11): 460-9.
54. Watters TM, Kenny EF, O’Neill LA. Structure, function and regulation of the Toll/IL-1 receptor adaptor proteins. Immunol Cell Biol 2007; 85(6): 411-9.
55. Triantafilou M, Triantafilou K. Lipopolysaccharide recognition: CD14: TLRs and the LPS-activation cluster. Trends Immunol 2002; 23(6): 301-4.
56. Kielian T. Toll-like receptors in central nervous system glial inflammation and homeostasis. J Virol 2006; 83(5): 11362-9.
57. Reed-Geaghan EG, Reed QW, Cramer PE, Landreth GE. Deletion of CD14 attenuates Alzheimer’s disease pathology by influencing the brain’s inflammatory milieu. J Neurosci 2010; 30(46): 15369-773.
58. Baumann CL, Aspalter IM, Sharif O, et al. CD14 is a coreceptor of Toll-like receptors 7 and 9. J Exp Med 2010; 207(12): 2689-701.
59. Hoebe K, Georgel P, Rutschmann S, et al. CD36 is a sensor of diacylglycerides. Nature 2005; 433(7025): 523-7.
60. Triantafilou M, Gamper FG, Haston RM, et al. Membrane sorting of toll-like receptor (TLR)-2/6 and TLR2/1 heterodimers at the cell surface determines heterotypic associations with CD36 and intracellular targeting. J Biol Chem 2006; 281(4): 31002-11.
61. Stewart CR, Stuart LM, Wilkinson K, et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol 2010; 11(2): 155-61.
62. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006; 6(11): 823-35.
63. Akira S. Innate immunity to pathogens: diversity in receptors for microbial recognition. Immunol Rev 2009; 227(1): 5-8.
64. Bernier LP. Purinergic regulation of inflammasome activation after central nervous system injury. J Gen Physiol 2012; 140(5): 571-5.
65. Oh JE, Lee HK. Modulation of pathogen recognition by autophagy. Front Immunol 2012; 3: 44.
66. Wilkinson K, El Khoury J. Microglial scavenger receptors and their roles in the pathogenesis of Alzheimer’s disease. Int J Alz Dis 2012; 489456.
67. Gambuzza M, Licata N, Palella E, et al. Targeting Toll-like receptors: emerging therapeutics for multiple sclerosis management. J Neuroimmunol 2011; 239(1-2): 1-12.
68. Bsibsi M, Ravid R, Gveric D, van Noort JM. Broad expression of Toll-like receptors in the human central nervous system. J Neuropathol Exp Neurol 2002; 61(11): 1013-21.
69. Lehnardt S, Lachance C, Patrizi S, et al. The Toll-like receptor TLR4 is necessary for lipopolysaccharide-induced oligodendrocyte injury in the CNS. J Neurosci 2002; 22(7): 2478-86
70. Jack CS, Arbour N, Manusow J, et al. TLR signaling tailors innate immune responses in human microglia and astrocytes. J Immunol 2005; 175(7): 4320-30.
71. Lehnardt S, Henneke P, Lien E, et al. A mechanism for neurodegeneration-induced by group B streptococci through activation of TLR2/MyD88 pathway in microglia. J Immunol 2006; 177(1): 583-92.
72. Town T, Jeng D, Alexopoulou L, Tan J, Flavell RA. Microglia recognize double-stranded RNA via TLR3. J Immunol 2006; 176(6): 3304-12.
73. Lafon M, Megret F, Lafage M, Prehaud C. The innate immune facet of brain: human neurons express TLR3 and sense viral dsRNA. J Mol Neurosci 2006; 29(3): 185-94.
74. Ma Y, Li J, Chiu I, et al. Toll-like receptor 8 function as a negative regulator of neurite outgrowth and inducer of neuronal apoptosis. J Cell Biol 2006; 175(2): 209-15.
75. Cameron JS, Alexopoulou L, Sloane JA, et al. Toll-like receptor 3 is a potent regulator of axonal growth in mammals. J Neurosci 2007; 27(47): 13033-41.
76. Kim D, Kim MA, Cho IH, et al. A critical role of TLR2 in nerve injury-induced spinal cord glial cell activation and pain hypersensitivity. J Biol Chem 2007; 282(20): 14975-83.
77. McCusker RH, Kelley KW. Immune-neural connections how the immune system’s response to infectious agents influences behavior. J Exp Biol 2013; 216(Pt 1): 84-98.
78. Overdahl A, Levine B. Eating the enemy within: autophagy in infectious diseases. Cell Death Differ 2009; 16(1): 57-69.
79. Travassos LH, Carneiro LA, Ramjeet M, et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol 2010; 11(1): 55-62.
80. Yano T, Kurata S. Intracellular recognition of pathogens and autophagy as an innate immune host defence. J Biochem 2011; 150(2): 143-9.
81. Acosta C, Davies A. Bacterial lipopolysaccharide regulates nociceptin in sensory neurons. J Neurosci Res 2008; 86(5): 1077-86.
82. Pandey S, Agrawal DK. Immunobiology of Toll-like receptors: emerging trends. Immunol Cell Biol 2006; 84(4): 333-41.
83. Lehnardt S, Schott E, Trimbuch T, et al. A vicious cycle involving release of heat shock protein 60 from injured cells and activation of toll-like receptor 4 mediates neurodegeneration in the CNS. J Neurosci 2008; 28(10): 2320-31.
84. Miyake K. Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin Immunol 2007; 19(1): 3-10.
85. Liu Y, Chen GY, Zheng P. CD24-Siglec G/10 discriminates danger- from pathogen-associated molecular patterns. Trends Immunol 2009; 30(12): 557-61.
86. Shimada M, Yanai Y, Okazaki T, et al. Hyaluronan fragments generated by sperm-secreted hyaluronidase stimulate cytokine/chemochine production via the TLR2 and TLR4 pathway in cumulus cells of ovulated COCs, which may enhance fertilization. Development 2008; 135(11): 2001-11.
87. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007; 13(5): 552-9.
88. Sloane JA, Blitz D, Margolin Z, Vartarian T. A clear and present danger: endogenous ligands of Toll-like receptors. Neuromol Med 2010; 12(2): 149-63.
89. Hanisch U-K, Johnson TV, Kipnis J. Toll-like receptors: roles in neuroprotection? Trends Neurosci 2008; 31(4): 176-82.
90. Tahara K, Kim HD, Jin JJ, et al. Role of TLR signaling in Aβuptake and clearance. Brain 2006; 129(Pt 11): 3006-19.
91. Blander JM, Medzhitov R. Regulation of phagosome maturation by signals from toll-like receptors. Science 2004; 304(5673): 1014-8.
92. Doyle SE, O’Connell RM, Miranda GA, et al. Toll-like Receptors induce a phagocytic gene program through p38. J Exp Med 2004; 199(1): 81-90.
93. Rideout HJ, Lang-Rolling I, Stefanis L. Involvement of macroautophagy in the dissolution of neuronal inclusions. Int J Biochem Cell Biol 2004; 36(12): 2551-62.
94. Hara T, Nakamura K, Matsui M, et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 2006; 441(7095): 885-9.
95. Komatsu M, Waguri S, Chiba T, et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 2006; 441(7095): 880-4.
96. Klionsky DJ, Elazar Z, Seglen PO, Rubinsztein DC. Does bafilomycin A1 block the fusion of autophagosomes with lysosomes? Autophagy 2008; 4(7): 849-950.
97. Shi CS, Kehrl JH. MyD88 and TRIF target beclin 1 to trigger autophagy in macrophages. J Biol Chem 2008; 283(48): 33175-82.
98. Martinez-Vicente M, Cuervo AM. Autophagy and neurodegeneration: when the cleaning crew goes on strike. Lancet Neurol 2007; 6(4): 352-61.
99. Dewitt A, Moffatt OD, Raykundalia C, et al. Human CD14 mediates recognition and phagocytosis of apoptotic cells. Nature 1998; 392(6675): 505-9.
100. Takuma K, Fang F, Zhang W, et al. RAGE-mediated signaling contributes to intraneuronal transport of amyloid-β and neuronal dysfunction. Proc Natl Acad Sci USA 2009; 106(47): 20021-6.
101. Fuentealba RA, Liu Q, Zhang J, et al. Low-density lipoprotein receptor-related protein 1 (LRP1) mediates neuronal Aβ42 uptake and lysosomal trafficking. PLoS One 2010; 5(7): e11884.
102. Lee CYD, Landreth GE. The role of microglia in amyloid clearance from the AD brain. J Neural Transm 2010; 117(8): 949-60.
103. Vernon PJ, Tang D. Eat-me: autophagy, phagocytosis, and reactive oxygen species signaling. Antioxid Redox Signal 2012; 18(6): 677-91.
104. Koprich JB, Reske-Nielsen C, Mithal P, Isacson O. Neuroinflammation mediated by IL-1β increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease. J Neuroinflammation 2008; 5: 8.
105. Sabroe I, Parker LC, Dower SK, Whyte MK. The role of TLR activation in inflammation. J Pathol 2008; 214(2): 126-35.
106. Deleidi M, Hallett PJ, Koprich JB, Chung CY, Isacson O. The tolllike receptor-3 agonist polyinosinic:polycytidylic acid triggers nigrostriatal dopaminergic degeneration. J Neurosci 2010; 30(48): 16091-101.
107. Rogers J, Shen Y. A perspective on inflammation in Alzheimer’s disease. Ann NY Acad Sci 2000; 924: 132-5.
108. Holmes C, Butchart J. Systemic inflammation and Alzheimer’s disease. Biochem Soc Trans 2011; 39(4): 898-901.
109. Zotova E, Nicoll JA, Kalaria R, Holmes C, Boche D. Inflammation in AD: relevance to pathogenesis and therapy. Alzheimers Res Ther 2010; 2(1): 1.
110. Van Duijn CM, Hofman A, Nagelkerken L. Serum levels of interleukin-6 are not elevated in patients with Alzheimer's disease. Neurosci Lett 1990; 108(3): 350-4.
111. Alvarez XA, Franco A, Fernandez-Novoa L, Cacabelos R. Blood levels of histamine, IL-1 beta, and TNF-alpha in patients with mild to moderate Alzheimer disease. Mol Chem Neuropathol 1996; 29(2-3): 237-52.
112. Cacabelos R, Alvarez XA, Franco-Maside A, Fernandez-Novoa L, Caamano J. Serum tumor necrosis factor (TNF) in Alzheimer's disease and multi-infarct dementia. Methods Find Exp Clin Pharmacol 1994; 16(4): 2-35.
113. Richartz E, Stransky E, Baltra A, et al. Decline of immune responsiveness: a pathogenetic factor in Alzheimer disease? J Psychiatr Res 2005; 39(5): 535-43.
114. Ray S, Britschgi M, Herbert C, et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins Nat Med 2007; 13(11): 1359-62.
115. Licastro F, Pedrini S, Caputo L, et al. Increased plasma levels of interleukin-1: interleukin-6: and alphachymotrypsin in patients with Alzheimer’s disease: Peripheral inflammation or signals from the brain? J Neuroimmunol 2000; 103(1): 97-102.
116. De Luigi A, Fragiacomo C, Lucca U, et al. Inflammatory markers in Alzheimer’s disease and multi-infarct dementia. Mech Ageing Dev 2001; 122(16): 1985-95.
117. De Luigi A, Pizzimenti S, Quadri P, et al. Peripheral inflammatory response in Alzheimer’s disease and multiinfarct dementia. Neurobiol Dis 2002; 11(2): 308-14.
118. Zuliani G, Ranzini M, Guerra G, et al. Plasma cytokines profile in older subjects with late onset Alzheimer’s disease or vascular dementia. J Psychiatr Res 2007; 41(8): 686-93.
119. Bermejo P, Martí-Aragón S, Benedí J, et al. Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer’s disease. Immunol Lett 2008; 117(2): 198-202
120. Kamer AR, Craig RG, Pirraglia E, et al. TNF-alpha antibodies to periodontal bacteria discriminate between Alzheimer’s disease patients and normal subjects. J Neuroimmunol 2009; 216(1-2): 92-7.
121. Lee KS, Chung JH, Choi TK, et al. Peripheral cytokines and chemokines in Alzheimer’s disease. Dement Geriatr Cogn Disord 2009; 28(4): 281-7.
122. Pizza V, Agresta A, D’Acunto CW, Festa M, Capasso A. Neuroinflamm-aging and neurodegenerative diseases: an overview. CNS Neurol Disord Drug Targets 2011; 10(5): 621-34.
123. Woitera M, Sobów T, Kloszewska I, et al. Expression of immunohistochemical markers on microglia in Creutzeldt-Jakob disease and Alzheimer’s disease: morphometric study and review of the literature. Folia Neuropathol 2012; 50(1): 74-84.
124. Schmidt R, Schmidt H, Curb JD, et al. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study Ann Neurol 2002; 52(2): 168-74.
125. Engelhart MJ, Geerlingsm MI, Meijer J, et al. Inflammatory proteins in plasma and the risk of dementia: the Rotterdam study. Arch Neurol 2004; 61(5): 668-72.
126. Tilvis RS, Kahonen-Vare MH, Jolkkonen J, et al. Predictors of cognitive decline and mortality of aged people over a 10-year period. J Gerontol A Biol Sci Med Sci 2004; 59(3): 268-74.
127. Kuo HK, Yen CJ, Chang CH, et al. Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis. Lancet Neurol 2005; 4(6): 371-80.
128. Tan ZS, Beiser AS, Vasan RS, et al. Inflammatory markers and the risk of Alzheimer disease: the Framingham study. Neurology 2007; 68(22): 1902-8.
129. Tarkowski E, Andreasen N, Tarkowski A, Blennow K. Intrathecal inflammation precedes development of Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2003; 74(9): 1200-5.
130. Galimberti D, Venturelli E, Fenoglio C, et al. Intrathecal levels of IL-6: IL-11 and LIF in Alzheimer's disease and frontotemporal lobar degeneration. J Neurol 2008; 255(4): 539-44.
131. McCoy MK, Tansey MG. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation 2008; 5: 45.
132. Griffin WS, Sheng JG, Royston MC, et al. Glial-neuronal interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression. Brain Pathol 1998; 8(1): 65-72.
133. Town T, Nikolic V, Tan J. The microglial “activation” continuum: from innate to adaptive responses. J Neuroinflammation 2005; 2: 24.
134. Tuppo EE, Arias HR. The role of inflammation in Alzheimer’s disease. Int J Biochem Cell Biol 2005; 37(2): 289-305.
135. Gadad BS, Britton GB, Rao KS. Targeting oligomers in neurodegenerative disorders: lessons from α-synuclein, tau, and amyloid-β peptide. J Alzheimers Dis 2011; 24(Suppl 2): 223-32.
136. Selkoe DJ. Clearing the brain’s amyloid cobwebs. Neuron 2001; 32(2): 177-80.
137. Crouch PJ, Harding SM, White AR, et al. Mechanisms of A beta mediated neurodegeneration in Alzheimer’s disease. Int J Biochem Cell Biol 2008; 40(2): 181-98.
138. Landreth GE, Reed-Geaghan EG. Toll-like receptors in Alzheimer’s disease. Curr Top Microb Immunol 2009; 336: 137-53.
139. Selkoe D, Mandelkow E, Holtzman D. Deciphering Alzheimer disease. Cold Spring Harb Perspect Med 2012; 2(1): 011460.
140. Lindberg C, Hjorth E, Post C, Winblad B, Schultzberg M. Cytokine production by a human microglial cell line: effects of β-amyloid and α-melanocyte-stimulating hormone. Neurotox Res 2005; 8(3- 4): 267-76.
141. Halliday G, Robinson SR, Shepherd C, Kril J. Alzheimer’s disease and inflammation: a review of cellular and therapeutic mechanisms. Clin Exp Pharmacol Physiol 2000; 27(1-2): 1-8.
142. Brown GC, Bal-Price A. Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria. Mol Neurobiol 2003; 27(3): 325-55.
143. Rubio-Perez JM, Morillaz-Ruiz JM. A rewiev: inflammatory process in Alzheimer's disease, role of cytokines. Sci World J 2012; 756357.
144. Griffiths MR, Gasque P, Neal JW. The regulation of the CNS innate immune response is vital for the restoration of tissue homeostasis (repair) after acute brain injury: a brief review. Int J Inflam 2010; 151097.
145. El Khoury J, Luster AD. Mechanisms of microglia accumulation in Alzheimer’s disease: therapeutic implications. Trends Pharmacol Sci 2008; 29(12): 626-32.
146. Hung S-Y, Wang W-P, Liou H-C, Fu W-M. Autophagy protects neuron from Aβ-induced neurotoxicity. Autophagy 2009; 5(4): 502-10.
147. Harris H, Rubinsztein DC. Control of autophagy as a therapy for neurodegenerative disease. Nat Rev Neurol 2011; 8(2): 108-17.
148. Nixon RA, Wegiel J, Kumar A, et al. Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. J Neuropathol Exp Neurol 2005; 64(2): 113-22.
149. Boland B, Kumar A, Lee S, et al. Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer’s disease. J Neurosci 2008; 28(27): 6926-37.
150. Fiala M, Cribbs DH, Rosenthal M, Bernard G. Phagocytosis of amyloid-beta and inflammation: two faces of innate immunity in Alzheimer’s disease. J Alzheimers Dis 2007; 11(4): 457-63.
151. Feng Y, Li L. Monocytes in Alzheimer’s Disease. Neurosci Bull 2011; 27(2): 115-22.
152. Drouin-Quellet J, Cicchetti F. Inflammation and neurodegeneration: the story “retolled”. Trends Pharmacol Sci 2012; 33(10): 542-51.
153. Szekely CA, Thorne JE, Zandi PP, et al. Nonsteroidal antiinflammatory drugs for the prevention of AD. Neuroepidemiology 2004; 23(4): 159-69.
154. Northwestern University. www.northwestern.edu/newscenter/storie s/2012/07/brain-inflamation-drug.html
155. Letiembre M, Liu Y, Walter S, et al. Screening of innate immune receptors in neurodegenerative diseases: a similar pattern. Neurobiol Aging 2009; 30(5): 759-68.
156. Streit WJ, Miller KR, Lopes KO, Njie E. Microglial degeneration in the aging brain-bad news for neurons? Front Biosci 2008; 13: 3423-38.
157. Walter J, Schulz-Schuffer W, Fassbender K. Role of the toll-like receptor 4 in neuroinflammation in Alzheimer’s disease. Cell Physiol Biochem 2007; 20(6): 947-56.
158. Nixon RA, Cataldo AM. Lysosomal system pathways: genes to neurodegeneration in Alzheimer’s disease. J Alzheimers Dis 2006; 9(3 Suppl): 277-89.
159. Ihara Y, Maho Morishima-Kawashima M, Nixon R. The Ubiquitin- Proteasome System and the Autophagic–Lysosomal System in Alzheimer Disease. Cold Spring Harb Perspect Med 2012; 2(8): 006361.
160. Halle A, Homung V, Petzold GC, et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 2008; 9(8): 857-65.
161. Davis BK, Wen H, Ting JPY. The inflammasome NLRs in immunity, inflammation, and associated diseases. Ann Rev Immunol 2011; 29: 707-35.
162. Jana M, Palencia CA, Pahan K. Fibrillar amyloid-β peptides activate microglia via TLR2: implications for Alzheimer’s disease. J Immunol 2008; 181(10): 7254-62.
163. Fassbender K, Walter S, Kühl S, et al. The LPS receptor (CD14) links innate immunity with Alzheimer’s disease. FASEB J 2004; 18(1): 203-5.
164. Liu Y, Walter S, Stagi M, et al. LPS receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid peptide. Brain 2005; 128(Pt 8): 1778-89.
165. Xu Y, Jagannath C, Liu XD, et al. Toll-like receptor 4 is a sensor for autophagy associated with innate immunity. Immunity 2007; 27(1): 135-44.
166. Delgado MA, Elmaoued RA, Davis AS, Kyei G, Deretic V. TLR control autophagy. EMBO 2008; 27(7): 1110-21.
167. Richard KL, Filali M, Préfontaine P, Rivest S. Toll-like receptor 2 acts as a natural innate immune receptor to clear Aβ(1-42) and delay the cognitive decline in a mouse model of Alzheimer disease. J Neurosci 2008; 28(22): 5784-93.
168. Udan ML, Ajit D, Crouse NR, Nichols MR. Toll-like receptors 2 and 4 mediate Aβ(1-42) activation of the innate immune response in a human monocytic cell line. J Neurochem 2008; 104(2): 524-33.
169. Schütze S, Loleit T, Zeretzke M, et al. Additive microglialmediated neuronal injury caused by amyloid-βand bacterial TLR agonists in murine neuron-microglia co-coltures quantified by an automated image analysis using cognition network technology. J Alzheimers Dis 2012; 31(3): 651-7.
170. Trudler D, Farfara D, Frenkel D. Toll-Like receptors expression and signaling in glia cells in neuro-amyloidogenic diseases: towards future therapeutic application. Mediators Inflamm 2010; 497987.
171. Noda M, Suzumura A. Sweepers in the CNS: microglial migration and phagocytosis in the Alzheimer disease pathogenesis. Int J Alzheimers Dis 2012; 891087.
172. Vasselon T, Hailman E, Thieringer R, Detmers PA. Internalization of monomeric lipopolysaccharide occurs after transfer out of cell surface CD14. J Exp Med 1999; 190(4): 509-21.
173. Schmitz G, Orsó E. CD14 signaling in lipid rafts: new ligands and co-receptors. Curr Opin Lipidol 2002; 13(5): 513-21.
174. Gregory CD, Devitt A. CD14 and apoptosis. Apoptosis 1999; 4(1): 11-20.
175. Bate C, Veerhuis R, Eikelenboom P, Williams A. Microglia kill Aβ(1-42) damaged neurons by a CD14-dependent process. Neuroreport 2004; 15(9): 1427-30.
176. Jin JJ, Kim HD, Maxwell JA, Li L, Fukuchi K. TLR4-dependent up-regulation of cytokines in a transgenic mouse model of Alzheimer’s disease. J Neuroinflammation 2008; 29: 5-23.
177. Bate C, Kempster S, Williams A. Prostaglandin D2 mediates neuronal damage by amyloid-beta or prions which activates microglial cells. Neuropharmacology 2006; 50(2): 229-37.
178. Carpentier PA, Duncan DS, Miller SD. Glial toll-like receptor signaling in central nervous system infection and autoimmunity. Brain Behav Immun 2008; 22(2): 140-7.
179. Bamberger ME, Harris ME, McDonald DR, Husemann J, Landreth GE. A cell surface receptor complex for fibrillar β-amyloid mediates microglial activation. J Neurosci 2003; 23(7): 2665-74.
180. Koenigsknecht J, Landreth GE. Microglial phagocytosis of fibrillar Aβ-amyloid through a β1 integrin-dependent mechanism. J Neurosci 2004; 24(44): 9838-46.
181. Persaud-Sawin DA, Banach L, Harry J. Raft aggregation with specific receptors recruitment is required for microglial phagocytosis of Aβ42. Glia 2009; 57(3): 320-35.
182. Moore KJ, El Khoury J, Medeiros LA, et al. A CD36-initiated signaling cascade mediates inflammatory effects of β-amyloid. J Biol Chem 2002; 277(49): 47373-9.
183. El Khoury J, Moore KJ, Means TK, et al. CD36 mediates the innate host response to β-amyloid. J Exp Med 2003; 197(12): 1657-66.
184. Oldenborg PA, Zheleznyak A, Fang YF, et al. Role of CD47 as a marker of self on red blood cells. Science 2000; 288(5473): 2051-4.
185. Niederhoffer N, Lew R, Sick E, et al. Amyloid beta peptides trigger CD47-dependent mast cell secretory and phagocytic responses. Int J Immunopathol Pharmacol 2009; 22(2): 473-83.
186. Chen K, Zhang L, Huang J, et al. Cooperation between NOD2 and TLR2 ligands in the up-regulation of mouse mFPR2: a G-protein coupled Abeta42 peptide receptor in microglial cells. J Leukoc Biol 2008; 83(6): 1467-75.
187. Tang SC, Lathia JD, Selvaraj PK, et al. Toll-like receptor-4 mediates neuronal apoptosis induced by amyloid beta-peptide and the membrane lipid peroxidation product 4-hydroxynonenal. Exp Neurol 2008; 213(1): 114-21.
188. Kariko K, Ni H, Capodici J, Lamphier M, Weissmann D. mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem 2004; 279(13): 12542-50.
189. Virgin HW, Levine B. Autophagy genes in immunity. Nat Immunol 2009; 10(5): 461-70.
190. Holmes C, Cunningham C, Zotova E, et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology 2009; 73(10): 768-74.
191. Field R, Campion S, Warren C, Murray C, Cunningham C. Systemic challenge with TLR3 agonist poly I:C induces amplified IFNα/βand IL-1β responses in the diseased brain and exacerbates chronic neurodegeneration. Brain Behav Immun 2010; 24(6): 996-1007.
192. Ginsberg SD, Crino PB, Hemby SE, et al. Predominance of neuronal mRNAs in individualAlzheimer’s disease senile plaques. Ann Neurol 1999; 45(2): 174-81.
193. Marcinkiewicz M. BetaAPP and furin mRNA concentrates in immature senile plaques in the brain of Alzheimer patients. J Neuropathol Exp Neurol 2002; 61(9): 815-29.
194. Lehmann SM, Krüger C, Park B, et al. An unconventional role for miRNA: let-7 activates Toll-like receptor 7 and causes neurodegeneration. Nat Neurosci 2012; 15(6): 827-35.
195. Doy Y, Mizuno T, Maki Y, et al. Microglia activated with the TLR9 ligand CpG attenuate oligomeric amyloid β neurotoxicity in vitro and in vivo models of Alzheimer’s disease. Am J Pathol 2009; 175(5): 2121-32.
196. Scholtzova H, Kascsak R., Bates KA, et al. Induction of TLR9 as a method for ameliorating AD-related pathology. J Neurosci 2009; 29(6): 1846-54.
197. Dalpke A, Schäfer M, Frey M, et al. Immunostimulatory CpGDNA activates murine microglia. J Immunol 2002; 168(10): 4854-63.
198. Ravindran C, Chengm YC, Liang SM. CpG-ODNs induces upregulated expression of chemokine CCL9 in mouse macrophages and microglia. Cell Immunol 2010; 260(2): 113-8.
199. Schmidt C. Immune system’s Toll-like receptors have good opportunity for cancer treatment. J Natl Cancer Inst 2006; 98(9): 574-5.
200. Krishnan J, Lee G. Drugs targeting Toll like receptors. Arch Pharm Res 2009; 32(11): 1485-502.
201. Safieh-Garabedian B, Mayasi Y, Saadé NE. Targeting neuroinflammation for therapeutic intervention in neurodegenerative pathologies: a role for the peptide analogue of thymulin (PAT). Expert Opin Ther Targets 2012; 16(11): 1065-73.
202. Winblad B, Andreasen N, Minthon L, et al. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer’s disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol 2012; 11(7): 597-604.
203. InvivoGen. Innovation within Reach. http://www.invivogen.com/ review-vaccine-adjuvants (accessed August 30: 2013).
204. Gnjatic S, Sawhney NB, Bhardwaj N. Toll-like receptor agonists: are they good adjuvants? Cancer J 2010; 16(4): 382-91.
205. Hedayat M, Takeda K, Rezaei N. Prophylactic and therapeutic implications of Toll-like receptor ligands. Med Res Rev 2012; 32(2): 294-325.
206. Lan T, Kandimalla DY, Bhagat L, et al. Stabilized immune modulatory RNA compound as agonists of TLR7 and 8. Proc Natl Acad Sci USA 2007; 104(34): 13750-5.
207. Simon MP, O’Donnell MA. Role of neutrophils in BCG immunotherapy for bladder cancer. Urol Oncol 2008; 26(4): 341-5.
208. Lu H, Yang Y, Gad E, et al. Polysaccharide krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cells. Clin Cancer Res 2011; 17(1): 67-76.
209. Guan Y, Omueti-Ayoade K, Mutha SK, Hergenrother PJ, Tapping RI. Identification of novel synthetic toll-like receptor 2 agonists by high throughput screening. J Biol Chem 2010; 285(31): 23755-62.
210. Mata-Haro V, Cekic C, Martin M, et al. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 2007; 316(5831): 1628-32.
211. Casella CR, Mitchell TC. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci 2008; 65(20): 3231-40.
212. Krieg AM. Toll-free vaccines. Nat Biotechnol 2007; 25(3): 303-5.
213. Niebuhr M, Mühlradt PF, Wittmann M, Kapp A, Werfel T. Intracutaneous injection of the macrophage-activating lipopeptide- 2 (MALP-2) which accelerates wound healing in mice a phase I trial in 12 patients. Exp Dermatol 2008; 17(12): 1052-6.
214. Garay RP, Viens P, Bauer J, et al. Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help. Eur J Pharmacol 2007; 563(1-3): 1-17.
215. Goldman M. Translational Mini-Review Series on Toll-like Receptors: Toll-like receptor ligands as novel pharmaceuticals for allergic disorders. Clin Exp Immunol 2007; 147(2): 208-16.
216. Butts C, Murray N, Maksymiuk A, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-smallcell lung cancer. J Clin Oncol 2005; 23(27): 6674-81.
217. Muzio M, Bosisio D, Polentarutti N, et al. Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J Immunol 2000; 164(11): 5998-6004.
218. Zarember KA, Godowski PJ. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol 2002; 168(2): 554-61.
219. Sugiyama T, Hoshino K, Saito M, et al. Immunoadjuvant effects of polyadenylic:polyuridylic acids through TLR3 and TLR7. Int Immunol 2008; 20(1): 1-9.
220. Jasani B, Navabi H, Adams M. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer. Vaccine 2009; 27(25-26): 3401-4.
221. Hemispherx Biopharma, Inc. Available from: http://www.hemi spherx.net/content/investor/default.asp?goto=339; 93 (accessed June 02, 2008).
222. Nventa Biopharmaceutical Corp Safety study of HspE7 and Poly- ICLC given in patients with cervical intraepithelial neoplasia. Available from: http://clinicaltrials.gov/ct2/show/NCT00493545? term=Nventa&rank=2.html (accessed August IPH 28, 2013).
223. 3102-TLR3 agonist- Targeted oncology therapeutic agent. Available from: http://www.innate-pharma.com/rna-targeting-tlr (accessed April 02, 2009).
224. Pharma. The essential source of biopharmaceutical and pharmaceutical industry news. Available from: http://www. pharma-mag.com/genisphere-and-multicell-partner-to-delivermima- therapeutic-using-dendrimers (accessed August 07, 2013).
225. R & D Focus Drug News. CQ 07001 TNO, Clinquest licensing agreement. Available from: http://www.highbeam.com/doc/1G1- 161564190.html (accessed March 12, 2007).
226. Whiteside TL, Gulley JL, Clay TM, Tsang KY. Immunologic monitoring of cellular immune responses in cancer vaccine therapy. J Biomed Biotechnol 2011; 2011: 370374.
227. Yi J, Jung YJ, Choi S., Hwang J, Chung E. Autophagy-mediated anti-tumoral activity of Imiquimod in Caco-2 cells. Biochem Biophys Res Commun 2009; 386(3): 455-8.
228. Ma F, Zhang J, Zhang J, Zhang C. The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice. Cell Mol Immunol 2010; 7(5): 381-8.
229. Harrison LI, Astry C, Kumar S, Yunis C. Pharmacokinetics of 852A, an imidazoquinoline Toll-like receptor 7-specific agonist, following intravenous, subcutaneous, and oral administrations in humans. J Clin Pharmacol 2007; 47(8): 962-9.
230. Bergmann JF, de Bruijne J, Hotho DM, et al. Randomised clinical trial anti-viral activity of ANA 773: an oral inducer of exogenous interferons acting via TLR7: in chronic HCV. Aliment Pharmacol Ther 2011; 34(4): 443-53.
231. Wang D, Procopio M, Reardon M, et al. IMO-4200; a novel TLR7 and TLR8 dual agonist, enhances antitumor effect of ofatumumab, rituximab and cytotoxics in preclinical models of hematological malignancies. Idera Pharmaceutical Inc 2001; 3724.
232. Wisniewski T, Spinner D, Scholtzova H, Kascsak R. Preventing and treating amyloid-beta deposition by stimulation of innate immunity. Patent US 20110060035 2011.
233. Idera Pharmaceuticals. IMO-2055; a TLR9 agonist, is the lead candidate in the Company’s oncology program. Available from: http://www.iderapharma.com/clinical/cancer.html (accessed 2012).
234. Idera Pharmaceuticals. Respiratory diseases: IMO-2134; a TLR9 agonist, is a lead candidate for development in ashma and allergy indications. Available from: http://www.iderapharma.com/partne ring/respiratory.html (accessed 2012).
235. Friedberg JW, Kelly JL, Neuberg D, et al. Phase II study of a TLR- 9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br J Haematol 2009; 146(3): 282-91.
236. Vollmer J, Krieg AM. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev 2009; 61(3): 195-204.
237. Harandi AM, Davies G, Olesen OF. Vaccine adjuvants scientific challenges and strategic initiatives. Expert Rev Vaccines 2009; 8(3): 293-8.
238. Mologen AG. Focus on cancer therapies. DNA-based therapy as the main driver. Available from: http://s3.amazonaws.com/zanran_ storage/www.mologen.com/ContentPages/46175022.pdf (accessed July 10, 2009).
239. Meng G, Rutz M, Schiemann M, et al. Antagonistic antibody prevents toll-like receptor 2-driven lethal shock-like syndromes. J Clin Invest 2004; 113(10): 1473-81.
240. Arslan F, de Kielijn DP, Timmers L, Doevendands PA, Pasterkamp G. Bridging innate immunity and myocardial ischemia/reperfusion in injury: the search for therapeutic targets. Curr Pharm Des 2008; 14(12): 1205-16.
241. Chang YC, Kao WC, Wang WY, Yang RB, Peck K. Identification and characterization of oligonucleotides that inhibit Toll-like receptor 2-associated immune responses. FASEB J 2009; 23(9): 3078-88.
242. Djordjevic M. SELEX experiments: new prospects, applications and data analysis in inferring regulatory pathways. Biomol Eng 2007; 24(2): 179-89.
243. Ledeboer A, Hutchinson MR, Watkins LR, Johnson KW. Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. Expert Opin Investig Drugs 2007; 16(7): 935-50.
244. Rolan P, Hutchinson MR, Johnson KW. Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological disease. Exp Opun Pharmacother 2009; 10(17): 2897-904.
245. Hodgkinson L. Digestive Disease Week. Turning Science into Medicine-part 2. Idrugs 2010; 13(7): 424-6.
246. Dunn-Siegrist I, Leger O, Daubeuf B, et al. Pivotal involvement of Fcgamma receptor IIA in the neutralization of lipopolysaccharide signaling via a potent novel anti-TLR4 monoclonal antibody 15C1. J Biol Chem 2007; 282(48): 34817-27.
247. Ungaro R, Fukata M, Hsu D, et al. A novel toll-like receptor 4 (TLR4) antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. Am J Physiol Gastrointest Liver Physiol 2009; 296(6): G1167-79.
248. Ehrentraut S, Lohner R, Schwederski M, et al. “In vivo” Toll-like receptor 4 antagonism restores cardiac function during endotoxemia. Shock 2011; 36(6): 613-20.
249. Tidswell M, La Rosa SP. Toll-like receptor-4 antagonist eritoran tetrasodium for severe sepsis. Expert Rev Anti Infect Ther 2011; 9(5): 507-20.
250. Johnson BJ, Le TT, Dobbin CA, et al. Heat shock protein 10 inhibits lipopolysaccharide-induced inflammatory mediator production. J Biol Chem 2005; 280(6): 4037-47.
251. Basith S, Manavalan B, Lee G, Kim SG, Choi S. Toll-like receptor modulators: a patent review (2006-2010). Expert Opin Ther Pat 2011; 21(6): 927-44.
252. Matsunaga N, Tsuchimori N, Matsumoto T, Ii M. TAK-242 (resatorvid): a small-molecule inhibitor of Toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules. Mol Pharmacol 2011; 79(1): 34-41.
253. Wang X, Loram LC, Ramos K, et al. Morphine activates neuroinflammation in a manner parallel to endotoxin. Proc Natl Acad Sci USA 2012; 109(16): 6325-30.
254. IMS Lifecycle R&D Focus part of IMS LifeCycle. Drug News 2009; 18(13): 34. Available from: http://www.tcl-pharma.com/1Tc LPharma/pdf/DrugNewsV18N13.pdf
255. Lee JS, Lee JY, Lee MY, Hwang DH, Youn HS. Acrolein with an alpha, beta-unsaturated carbonyl group inhibits LPS-induced homodimerization of toll-like receptor 4. Mol Cells 2008; 25(2): 253-7.
256. Cashman JR, Gagliardi S, Lanier M, et al. Curcumins promote monocytic gene expression related to β-amyloid and superoxide dismutase clearance. Neurodegener Dis 2012; 10(1-4): 274-6.
257. Hultqvist M, Nandakumar KS, Björklund U, Holmdah R. The novel small molecule drug Rabeximod is effective in reducing disease severity of mouse model of autoimmune disorders. Ann Rheum Dis 2009; 68(1): 130-5.
258. Hultqvist M, Nandakumar KS, Bjorklund U, Holmdahl R. Rabeximod reduces arthritis severity in mice by decreasing activation of inflammatory cells. Ann Rheum Dis 2010; 69(8): 1527-32.
259. Giusti P, Frascaroli G, Tammik C, et al. The novel anti-rheumatic compound Rabeximod impairs differentiation and function of human pro-inflammatory dendritic cells and macrophages. Immunobiology 2011; 216(1-2): 243-50.
260. Pawar RD, Ramanjaneyulu A, Kulkarni OP, et al. Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. J Am Soc Nephrol 2007; 18(6): 1721-6.
261. Duramad O, Fearon KL, Chang B, et al. Inhibitors of TLR9 act on multiple cell subsets in mouse and man “in vitro” and prevent death “in vivo” from systemic inflammation. J Immunol 2005; 174(9): 5193-200.
262. Trieu A, Roberts TL, Dunn JA, Sweet MJ, Stacey KJ. DNA motifs suppressing TLR9 responses. Clin Rev Immunol 2006; 26(6): 527- 44.
263. Barrat FJ, Meeker T, Gregorio J, et al. Nucleic acids of mammalian origin can act as EL for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 2005; 202(8): 1131-9.
264. Barrat FJ, Meeker T, Chan JH, Guiducci C, Coffman RL. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol 2007; 37(12): 3582-6.
265. Barrat FJ, Coffman RL. Development of TLR inhibitors for the treatment of autoimmune diseases. Immunol Rev 2008; 223: 271- 83.
266. Sullivan T, Atiee G, Bhagat L, et al. Safety and pharmacodynamics of IMO-3100; a novel Toll-like receptor antagonist for autoimmune and inflammatory diseases, in a rising single-dose phase I clinical trial. Proceedings of the 6th Annual Meeting of the Oligonucleotide Therapeutic Society being held in Dana Point California, October 20-23: 2010.
267. Leung R, Proitsi P, Simmons A, et al. Inflammatory proteins in plasma are associated with severity of Alzheimer’s disease. PLoS One 2013; 8 (6): e64971.
268. Van Bockstaele F, Holz JB, Revets H. The development of nanobodies for therapeutic applications. Curr Opin Investig Drugs 2009; 10(11): 1212-24.
269. Couture LA, Piao W, Ru LW, Vogel SN, Toshchakov VY. Targeting Toll-like Receptor (TLR) Signaling by Toll/Interleukin-1 Receptor (TIR) Domain-containing Adapter Protein/MyD88 Adapter-like (TIRAP/Mal)-derived Decoy Peptides. J Biol Chem 2012; 287(29): 24641-8.
270. Vaishnaw AK, Gollob J, Gamba-Vitalo C, et al. A status report on RNAi therapeutics. Silence 2010; 1(1): 14.
271. Chang CI, Lee TY, Yoo JW, et al. Branched, tripartite-interfering RNAs silence multiple target genes with long guide strands. Nucleic Acid Ther 2012; 22(1): 30-9.
272. Shaw AC, Goldstein DR, Montgomery RR. Age-dependent dysregulation of innate immunity. Nat Rev Immunol 2013; 13(12): 875-87.